Wall Street brokerages expect Axovant Gene Therapies Ltd (NASDAQ:AXGT) to report earnings of ($1.34) per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Axovant Gene Therapies’ earnings. The highest EPS estimate is ($0.70) and the lowest is ($1.91). Axovant Gene Therapies reported earnings of ($3.84) per share in the same quarter last year, which suggests a positive year over year growth rate of 65.1%. The firm is expected to report its next quarterly earnings results on Tuesday, August 6th.
On average, analysts expect that Axovant Gene Therapies will report full-year earnings of ($5.34) per share for the current financial year, with EPS estimates ranging from ($8.09) to ($3.49). For the next financial year, analysts anticipate that the firm will report earnings of ($3.59) per share, with EPS estimates ranging from ($3.69) to ($3.42). Zacks’ EPS calculations are an average based on a survey of research analysts that cover Axovant Gene Therapies.
Axovant Gene Therapies (NASDAQ:AXGT) last released its quarterly earnings results on Tuesday, June 11th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($1.70) by $1.25.
AXGT traded up $0.21 during midday trading on Thursday, reaching $6.88. The company had a trading volume of 1,500 shares, compared to its average volume of 304,505. The company has a current ratio of 2.63, a quick ratio of 2.63 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $150.58 million, a PE ratio of -0.82 and a beta of 1.28. Axovant Gene Therapies has a 12-month low of $3.81 and a 12-month high of $20.80. The business’s 50-day moving average price is $6.33.
In other Axovant Gene Therapies news, CEO Pavan Cheruvu purchased 7,500 shares of the company’s stock in a transaction that occurred on Friday, June 14th. The shares were bought at an average cost of $5.21 per share, for a total transaction of $39,075.00. The purchase was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 6.60% of the company’s stock.
Several hedge funds have recently made changes to their positions in AXGT. Primecap Management Co. CA purchased a new stake in shares of Axovant Gene Therapies during the 1st quarter valued at approximately $1,400,000. Marshall Wace LLP purchased a new stake in shares of Axovant Gene Therapies during the 1st quarter valued at approximately $272,000. Finally, Sphera Funds Management LTD. purchased a new stake in shares of Axovant Gene Therapies during the 1st quarter valued at approximately $6,794,000.
Axovant Gene Therapies Company Profile
Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.
Featured Article: What is a stock portfolio tracker?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.